MXPA05013076A - Isoindolin-1-one compounds as kinase inhibitors. - Google Patents

Isoindolin-1-one compounds as kinase inhibitors.

Info

Publication number
MXPA05013076A
MXPA05013076A MXPA05013076A MXPA05013076A MXPA05013076A MX PA05013076 A MXPA05013076 A MX PA05013076A MX PA05013076 A MXPA05013076 A MX PA05013076A MX PA05013076 A MXPA05013076 A MX PA05013076A MX PA05013076 A MXPA05013076 A MX PA05013076A
Authority
MX
Mexico
Prior art keywords
compounds
isoindolin
kinase inhibitors
useful
formula
Prior art date
Application number
MXPA05013076A
Other languages
Spanish (es)
Inventor
Douglas H Steinman
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA05013076A publication Critical patent/MXPA05013076A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds having the formula, (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds and compositions containing the compounds.
MXPA05013076A 2003-06-02 2004-06-02 Isoindolin-1-one compounds as kinase inhibitors. MXPA05013076A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45270103A 2003-06-02 2003-06-02
PCT/US2004/017105 WO2004108672A1 (en) 2003-06-02 2004-06-02 Isoindolin-1-one compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA05013076A true MXPA05013076A (en) 2006-03-09

Family

ID=33510373

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013076A MXPA05013076A (en) 2003-06-02 2004-06-02 Isoindolin-1-one compounds as kinase inhibitors.

Country Status (5)

Country Link
EP (1) EP1633710A1 (en)
JP (1) JP2006526648A (en)
CA (1) CA2527814A1 (en)
MX (1) MXPA05013076A (en)
WO (1) WO2004108672A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
US20050182061A1 (en) * 2003-10-02 2005-08-18 Jeremy Green Phthalimide compounds useful as protein kinase inhibitors
BRPI0606872A2 (en) * 2005-01-28 2009-07-21 Novartis Ag use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
US7745641B2 (en) 2005-04-19 2010-06-29 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
WO2006134989A1 (en) * 2005-06-15 2006-12-21 Kyowa Hakko Kogyo Co., Ltd. Nitrogenated heterocyclic compound
TW200728277A (en) * 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
BRPI0613958A2 (en) 2005-06-29 2011-02-22 Palau Pharma Sa bicyclic compound, its use as a p38 inhibitor and pharmaceutical composition containing the same
WO2007000337A1 (en) * 2005-06-29 2007-01-04 Palau Pharma, S.A. Bicyclic derivatives as p38 kinase inhibitors
JP5193876B2 (en) * 2005-12-02 2013-05-08 バイエル・ヘルスケア・エルエルシー Pyrrolotriazine derivatives useful for treating cancer by inhibition of Aurora kinase
PE20070855A1 (en) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
BRPI0619146A2 (en) * 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp Substituted 4-amino-pyrroltriazine derivatives useful in the treatment of disorders and hyperproliferative diseases associated with angiogenesis
EP2090570B1 (en) 2006-09-05 2011-11-09 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative
WO2008047831A1 (en) 2006-10-17 2008-04-24 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
US20100104567A1 (en) 2007-03-05 2010-04-29 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
DE102008022221A1 (en) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitors of human aldosterone synthase CYP11B2
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
NZ600954A (en) 2009-12-22 2013-11-29 Isoindolinone inhibitors of phosphatidylinositol 3-kinase
BR112015015477B1 (en) * 2012-12-28 2022-07-12 Crystalgenomics, Inc 2,3-DI-HYDRO-ISOINDOL-1-ONA DERIVATIVES AND METHODS OF USING THEM AS BTK INHIBITORS
JP6921846B6 (en) * 2016-03-16 2021-09-15 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Compounds and methods for kinase regulation and its indications
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Multi-cyclic aromatic compounds as factor d inhibitors
US11384065B2 (en) 2018-01-03 2022-07-12 Medshine Discovery Inc. Heterocyclic compound as CSF-1R inhibitor and use thereof
AU2021212669B2 (en) * 2020-01-29 2023-10-26 Gilead Sciences, Inc. GLP-1R modulating compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277847B1 (en) * 1999-04-02 2001-08-21 Fmc Corporation Herbicidal isoindolinonyl-and 3,4-dihydroisoquinolonyl-substituted heterocycles
DE10154113A1 (en) * 2001-11-03 2003-05-15 Opel Adam Ag Front structure of a motor vehicle
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors

Also Published As

Publication number Publication date
EP1633710A1 (en) 2006-03-15
WO2004108672A1 (en) 2004-12-16
CA2527814A1 (en) 2004-12-16
JP2006526648A (en) 2006-11-24

Similar Documents

Publication Publication Date Title
WO2006050109A3 (en) Novel kinase inhibitors
MXPA05012596A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors.
MXPA05013076A (en) Isoindolin-1-one compounds as kinase inhibitors.
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
MXPA06010904A (en) Tricyclic pyrazole kinase inhibitors.
MXPA03010207A (en) Novel 4-anilinoquinoline-3-carboxamides.
WO2007079164A3 (en) Protein kinase inhibitors
IL160915A0 (en) Indolizines inhibiting kinase proteins
YU84603A (en) Novel tyrosine kinase inhibitors
IL163781A0 (en) Purine derivatives as kinase inhibitors
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
ID27535A (en) PIRASOLA DURATION AS P-38 MAP KINASE INHIBITOR
IN2014DN06567A (en)
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
PL406680A1 (en) Tyrosine kinase inhibitors
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
MXPA03010961A (en) Thiazole compounds useful as inhibitors of protein kinases.
MXPA05009151A (en) Heterocyclic kinase inhibitors.
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
TW200510407A (en) Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
MXPA04006271A (en) Indolinone derivatives useful as protein kinase inhibitors.
MX2008002104A (en) 1-acyldihydropyrazol derivatives.
IL163777A0 (en) Kinase inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
UA85394C2 (en) Substituted quinolines as protein tyrosine kinase enzyme inhibitors

Legal Events

Date Code Title Description
FG Grant or registration